52nd Edition of GSC Awards-25–26 January 2027-Tokyo, Japan - Shinagawa Prince Hotel


 

The Global Scholar Awards is an international recognition platform dedicated to celebrating outstanding researchers, academicians, scientists, professors, and research professionals who have made significant contributions to their respective fields. The event recognizes academic excellence, innovative research, scientific discoveries, and impactful scholarly achievements that contribute to global knowledge and societal advancement.

Global Scholar Awards 🌟

Visit Our Website 🌐: globalscholarawards.com Nominate Now👍: https://globalscholarawards.com/doctor-awards-nobel-prize-scientists-award-nomination/?ecategory=Awards&rcategory=Awardee Contact us ✉️: info@globalscholarawards.com Get Connected Here: ================= Twitter : x.com/ScienceInventi1 Youtube : youtube.com/@nesinconferenceandawards4869 Pinterest : in.pinterest.com/scienceinventions/ Instagram : instagram.com/global_scholar_123 Linkedin : linkedin.com/in/global-scholar-awards-09664427b Blog : newscienceinventions2020.blogspot.com @WorldResearchAwards @GlobalScholarAwards #worldresearchawards #researchawards #researchexcellence #globalrecognition #academicawards #globalresearchawards #shorts #researchers #labtechnicians #awards #professors #teachers #lecturers #engineering

Protecting research, preserving collaboration: What UK leaders told us about research security

Research security is widening in scope faster than institutions can build the skills, tools and clarity to manage it. The central paradox facing science today is sharp: how do you protect critical R&D without suffocating the global collaboration it depends on? That was the question at the heart of a recent roundtable in London.

In October, Digital Science and Ulterior hosted an executive roundtable on securing R&D intelligence for UK and European funders and government institutions. The session brought seventeen guests from across government, funding bodies and research organisations together with the Digital Science team, including Dr Leslie McIntosh (VP, Research Integrity and Security) and Marko Zovko (Global Business Development Director, Government, Funder and Non-profit). 

The discussion focused on three core areas: the current landscape, practical challenges and best practices, and openness versus security. What emerged was a portrait of a research sector grappling with fragmented data, shifting definitions of dual use, and an urgent need for network-level clarity. 

The conversation ran without attribution, so what follows reflects what we heard around the tables, not the views of any individual or organisation.

Research security now reaches further

Dr. Leslie McIntosh set the scene by showing why research integrity is fundamental to research security, and how patterns in affiliations and collaboration networks can signal risk.

Dual use came up repeatedly. Some guests noted that certain funding is increasingly framed around dual-use potential, and that the concept is broadening into areas such as AI. Because the eventual application of a project (drones, for example) is often unclear, researchers may end up working on dual-use projects without realising it. Guests also described a tension between government pressure to produce more defence-relevant research and the need to secure it. 

Sovereignty pushed its way up the agenda, with guests stretching it well beyond geopolitics to cover data, IP and supply chains. Some guests raised concerns about IP, data assets and personal data coming under foreign or corporate control, and about where industry chooses to locate. Others described diversifying data services, including away from the largest commercial cloud providers, as part of staying safe, and saw “middle power” countries as a growth area for trusted collaboration.

Horizon scanning drew broad interest, along with a sobering framing. By the time a signal is visible, the next development has already begun. The “next best thing” is watched and protected, while the “next, next best thing” is unknown and at high risk.

The practical burden falls unevenly

The biggest gap guests named was skills and capacity. Upskilling researchers and institutional staff on research security is costly, and people already have little time for grant paperwork. Due diligence requirements can slow or stop research, with smaller, less-resourced institutions facing a heavy disadvantage. 

Sharing is hard, abroad and at home

Due diligence gets harder across borders. UK requirements can be incompatible with overseas partners’ policies and capabilities, which leaves researchers stuck and, some guests felt, places heavy demands on the very countries a grant is meant to support. 

The problem is no easier closer to home. Silos make it hard to move data inside government organisations, let alone across agencies and research bodies. 

The blind spot after the award

One of the biggest risks comes after the grant is awarded: guests described vetting of downstream collaborations, such as grant-funded start-ups and spin-offs, as extremely rare, even though they saw it as a major security concern for processes, personnel and IP. 

Incentives play a part

The publish-or-perish mentality persists, with few other ways to build credibility, though research blogs and alternative metrics were mentioned favourably. Research departments are increasingly expensive to run, and some guests felt that industry and defence bodies are using PhD students as a lower-cost research resource. Others said that unclear IP and data ownership holds back innovation before IP is even created.

From project-level checks to network-level questions

The European Commission’s principle of “as open as possible, as closed as necessary” was a natural reference point, not least because guests warned of a chilling effect on legitimate collaboration. Restrictions on foreign students, for example, aim to reduce risk but can hit institutions that depend on international students financially and for their research. We argued that making the principle real takes more than a compliance framework. Project-level questions, such as whether a grant is compliant, a partner is on a restricted list, or a researcher has disclosed all affiliations, can be answered, but they are not sufficient. 

The harder questions sit at network level: where capability is concentrated across a portfolio, which collaborations are load-bearing and which are peripheral, and where dependency is forming without anyone intending it. Marko Zovko set out what answering them requires: persistent identifiers used consistently across borders and agencies, linked data across funding, outputs and collaboration, and analytics that can surface what manual review cannot see at scale.

The regulatory picture adds urgency. Research security requirements under FP10 (the EU’s next framework programme), the EU Research Security Centre, a European due diligence platform and UKRI’s Trusted Research and Innovation principles are all moving forward at the same time. Applying “as open as possible” is what strategic governance looks like for a research system that has to stay internationally connected.

Key takeaways and next steps

Guests valued the mix of perspectives around the tables and the chance to meet peers from other organisations. One described the evening as “a good opportunity to engage with other professionals and explore the topic from different angles”. Several practical steps emerged from the discussion:

  • Ask network-level questions alongside project-level compliance checks.
  • Use persistent identifiers consistently across borders and agencies, and link data across funding, outputs and collaboration.
  • Invest in awareness training for researchers and institutional staff, particularly as dual use spreads into areas such as AI.
  • Support smaller institutions that lack the tools and capacity of larger universities.
  • Extend due diligence downstream to grant-funded start-ups and spin-offs.

A recurring reminder was that research security is about the motivations of the people involved, not only the research and its outputs. That means knowing the people behind the research as well as the research itself, and making that possible without making collaboration harder.

Our thanks go to Ulterior for partnering with us, and to every guest who joined us in London.

Balancing international collaboration with national security starts with connected data. Learn how Dimensions Research Security supports funders and institutions, or arrange a demo with one of our experts. 

The post Protecting research, preserving collaboration: What UK leaders told us about research security appeared first on Digital Science.



from Digital Science https://ift.tt/F7cQUzJ

Sci Foo heads to Singapore

The Digital Science and O’Reilly teams are getting ready to head to Science Foo Camp, and we’re excited because for the first time the event will be held in Singapore, thanks to sponsorship from Google and others.

In its 20th year, Sci Foo – as it’s known – is an “unconference” with no fixed agenda, and brings together researchers, innovators, technologists, communicators and policy makers from around the world who are doing groundbreaking work in diverse areas of science and technology. Attendance is by invitation only.

Sci Foo has long been rooted in the West, but research and innovation are increasingly global, and we wanted this event to reflect that. Singapore is a major R&D hub with a strong culture of working across disciplines and an easy meeting point for people from across the Asia-Pacific region and beyond. It is home to leading universities such as the National University of Singapore (NUS) and Nanyang Technological University (NTU), the national research agency Agency for Science, Technology and Research (A*STAR), and Google DeepMind’s first research lab in Southeast Asia.

The topics of discussion are truly wide-ranging, and typically include: climate and sustainability, medicine and disease, machine learning and AI, food systems, astrophysics, neuroscience, and the many ways technology is reshaping society, from health and the economy to politics and culture.

We’re looking forward to many conversations, “lightning talks” and catching up with our fellow organisers and attendees, old and new. We keep numbers modest and try to bring together people from as many fields and backgrounds as we can, and we’re always looking at how to widen who we hear from. After a successful Sci Foo in the UK in August, sponsored by ARIA, we’ve focused on inviting researchers from across the Asia-Pacific region, and we’re keen to learn from them.

Sci Foo simply couldn’t happen without the support of sponsors and supporters, and we’re enormously grateful to all of them. Thank you to our co-organisers Tim O’Reilly and Marsee Henon of O’Reilly Media, and Digital Science colleagues Cat Allman and Steve Leicht. Special thanks to Mira Lane and the many colleagues at Google who make this event possible, and to our other sponsors: the Alfred P. Sloan Foundation (whose support helped many attendees travel to Singapore), The Navigation Fund, Nature, and Daniel Hook of Holtzbrinck Publishing Group.

To understand more about Sci Foo, see this video from 2018, in which we asked a number of scientists what the future might hold, as well as this more recent one which explains, “What is Sci Foo?”


Photo of Singapore by Sami Kizilbash, searchforwild.com

The post Sci Foo heads to Singapore appeared first on Digital Science.



from Digital Science https://ift.tt/q7xAzWm

A patent cliff is approaching and billions hang in the balance. Quality patent data will be the dealbreaker.

190 high-earning drugs are likely to lose patent protection by 2030, clearing the path for generics and biosimilars to capitalize—but not all R&D teams are set up to succeed. 

In the age of AI, research intelligence has to begin with trusted data. This series, Inside Our Data, explores the foundational data infrastructure that makes trust possible.

According to Deloitte, 190 drugs—36% of which are considered “blockbusters”—are set to lose patent protection by 2030. 

This means pharma companies will be able to compete with these products, developing and distributing generic and biosimilar versions. At the same time, those firms who have held exclusivity will be looking for new opportunities, as greater availability will swiftly drive the prices of those drugs down. 

With an estimated $236B in revenue at risk, pharmas are racing to ensure swift and sound development work, often by establishing trustworthy, reliable, and explainable AI workflows.

But when it comes to AI, garbage in equals garbage out. 

In order to minimize risk and capitalize on market opportunity, there’s one thing R&D teams must have: rich up-to-date patent data. 

Patents can hold both risk and opportunity

A patent record contains myriad details that set out where and how an enterprise can operate, but what matters most is its legal status—who owns it, is it in force, and how might this vary across jurisdictions? Depending on the answers to these questions, the same record can mean protection, opportunity or risk for an R&D team. 

Parsing the status of patent records is made more complex because status can change subtly and between jurisdictions. Status differs by country, so single patents active in some designated states may be expired in others. 

A patent’s term can also vary by country. While pharmaceutical patents typically last for 20 years from filing, they can be extended up to five years in the EEA and US. For example, the semaglutide patent expired in March 2026 in many countries including China, while extensions stretch to 2031 in Europe and to at least 2032 in the US. These extensions are available because drugs can’t be sold until they clear years of clinical trials and regulatory review, such as FDA approval, which uses up part of the 20-year patent term before they some of that time, the US and Europe let companies extend their patent protection by up to five years. 

This means—even though a patent’s legal status is its most important characteristic—there’s often no simple answer to “is it in force?”

And each patent office, across the world, has its own systems: they use their own delivery structure, terminology and own original language, meaning raw records are nearly impossible to automatically compare. 

With millions of changes to record legal statuses every week globally, it can be difficult for R&D teams to be certain of their freedom to operate. But the cost of getting this wrong can be massive. 

Stale patent records can create existential risk

The first step of R&D is defining the freedom to operate; teams must search for in-force patents and published applications in their target jurisdictions. A lack of patents, or an expiring patent, can signal a new opportunity for a firm to expand. 

This is the first instance where stale patent data creates risk. A stale record can show a space in the market that no longer exists, or can show a patent to be in force when it isn’t. 

The risks associated with relying on stale data can be existential for firms. 

The median cost of bringing a drug to market is estimated at ~$985M—if a firm invests even a portion of this expenditure before realizing they lack freedom to operate, those costs may be sunk. 

This same logic can protect, or expose, a firm’s own portfolio. An expiry in one jurisdiction is visible to competitors, and patents are costly to obtain and maintain, so knowing what to renew or let lapse depends on having a clear view of current records. 

AI workflows make bad patent data more expensive

AI workflows are allowing R&D teams to work faster and smarter all over the world. These workflows can form a critical part of setting a strategic course—and anticipating the direction of travel for competitors. 

But stale data means bad outputs and material enterprise risk. An agent which accepts an outdated record can tell a company that a patent isn’t in force when it actually is—and the AI won’t know to question it. 

AI relies on structured and consistently labeled data. Mergers, divestments, name changes, and spin-offs with flawed corporate name mappings undermine the validity of AI outputs. The quest for consistency in patent data is troubled further by imprecise or varying translations of multi-lingual inputs from around the globe.

The only way to avoid this risk is using fresh, complete, curated data to feed those AI workflows. But the cost of preparing that data in-house is massive—and there are millions of record updates around the world every single week. 

To ensure teams have access to fresh and complete patent data from around the world, enterprises can access purpose-built curated data suites, such as IFI CLAIMS by Digital Science. 

Enterprises need to make the most of the data available

IFI CLAIMS has been addressing patent data challenges for more than 70 years. Patent data from around the world is captured, standardized, and unified into one of the industry’s most complete and dependable platforms, continuously updated and growing as patent offices deliver new information, giving teams a single reliable source for the latest global patent intelligence. 

IFI’s current data coverage includes 105+ countries with bibliographic data, 62 with full text and 180 million+ patent records. Full text and attachments give AI and data science teams the detail behind the invention. Attachments include cover pages, specifications, drawings, reference images and chemistry files. Patent data is ingested, translated and parsed automatically, and checked for both technical validation before going live, and continuous editorial domain expertise oversight. 

IFI supplies expiry dates, regulatory-extensions flags, terminal-disclaimers flags, standardized names and maps patents back to ultimate owners, their parent companies. 

These millions of weekly updates are fed live into IFI client databases, so they always reflect the latest status and ownership updates—ensuring high quality, accurate data and drastically reducing the ambiguity which often undermines an AI workflow. 

Patents form the backbone of a connected research lifecycle

Enterprises that can harness AI efficiently will pull ahead of competitors in the coming years, armed with greater competitive insight, strategic direction, and exposure mitigation. 

Those enterprises have the most to gain by embracing a fully connected research lifecycle with an intelligence partner like Digital Science. This lifecycle begins with Dimensions, which links grants, publications, citations, clinical trials, patents and policy documents in one place, covering how research is funded, published and moved toward clinical use. 

IFI CLAIMS supplies accurate and up-to-date patent data complete with ownership and legal status information that help define the R&D roadmap. And Altmetric captures mainstream and academic mentions of research from sources including news, blogs, policy documents, social media and patents, with 256m+ mentions of over 24 million research outputs. 

Applying an AI layer across all three of these tools can accompany a target from grant to publication, through trial activity and attention, to the strategic maintenance of the patent’s position and legal status. 

The common thread here is curated, structured, high quality data at every stage—from the first freedom to operate search to strategic patent extension decisions 20 years later.

With the right tools, patent data can be a strategic lever

AI is necessary for enterprises to remain competitive in today’s markets. But it’s only as good as the data under it, and for patents that means current status, correct ownership and country-by-country accuracy. 

Armed with trustworthy, always-fresh patent data, enterprises can get a clear and early view of an industry’s directions, define their own priorities, and seize new opportunities as they arise. 

IFI CLAIMS, as part of the Digital Science ecosystem, makes this possible.

The post A patent cliff is approaching and billions hang in the balance. Quality patent data will be the dealbreaker. appeared first on Digital Science.



from Digital Science https://ift.tt/Xwazjt4

Moving from reputation to reach: data-driven decision-making for Medical Affairs publication targets

Too often, familiarity and reputation guide target selection for scientific communications. Quantifiable asset performance metrics show the way to more effective publication targeting.

Compass Points: The Future of Medical Affairs is a series exploring the strategic challenges facing Medical Affairs teams in today’s communication landscape—and the tools that will help them get it right.

In the life sciences industries, submitting scientific communications for publication is the culmination of substantial investment. Assets such as research articles and conference abstracts provide valuable context to scientific and clinical data. This work underscores the data-driven mindset of modern Medical Affairs and publications teams.

Yet the selection of publication targets is often driven by qualitative, instead of quantitative, measures. Human bias easily informs journal and conference selection. When decisions result from long-established practice, from familiarity, or from reputation, they lack the fidelity of publication targeting based on defined metrics such as reach.

Publication performance metrics captured from integrated data sources help overcome these limitations. Data-driven choices about scientific communications publication targets are facilitated by measurement tools, such as Compass by Dimensions, characterized by user-defined benchmarking capabilities and publication performance tracking over time.

Incomplete data promotes biased decisions for scientific communications publication targets

For Medical Affairs and publications teams, selecting publication targets is a key element of evidence planning and communication to a variety of stakeholder audiences. Choosing the right publication target means that product-defining data are available to the intended readership, in accordance with strategically-defined time points in the product’s lifecycle. Adding to the complexity, data types, intended readership, and key product messaging will evolve over time. 

Furthermore, target selection encompasses a range of content types. This requires understanding which formats are appropriate for a given journal or professional meeting. Teams must decide where to publish peer-reviewed articles, reviews, communications, and other long-form structures, and where to submit primary and encore conference abstracts. Such decisions may still rely on only a limited number of traditional metrics; known examples include journal impact factor, average number of referencing citations per published work, or visits to a publication’s webpage. 

However, when availability of publication performance data is limited in this way, instead of thorough, metrics-grounded decision-making, teams turn to qualitative influences. Though provocative, the statement “Better the devil you know” characterizes a persistent, biased, and even emotional selection based on long familiarity with a journal, conference, or editorial team. Despite its ambiguous definition, the reputation of a given journal or meeting in the industry may strongly bias the choice of publication target. As described below, author preferences can also play a role.

Real-world example: which conference to choose?

A new pharmaceutical drug product is in its first year of launch in multiple EMEA markets. Further commercial launches are planned for this region over the next two years. While the therapeutic area is established within the global organization, the product’s treatment modality is new. In this critical lifecycle stage, the Senior Director, Scientific Communications is responsible for the region’s conference publication strategy.

All the elements are in place: robust Launch Excellence structures, the Integrated Evidence Plan, established relationships with Key External Experts (KEES). Up to now, however, the abundance and variety of relevant local-market and EMEA-regional conferences have been difficult to navigate. The KEES are highly engaged, sharing their own recommendations and interests for conferences to target. They expect that these interests will be taken well into consideration during conference decision-making.

How should scientific communications teams structure conference data submission? Going forward, how can our Senior Director colleague make data-driven decisions, instead of selections based on the company’s past conference attendance, or on stakeholder preference?

Without knowledge of reach, critical timelines and audiences are underprioritized

As explored in the first installment of this Compass Points blog series, reach is a quantitative measure of information propagating across channels or networks; for example, in news, social media, podcasting, or clinical commentary. It is a key performance metric for scientific communications.

When publications professionals lack the ability to select publishers, journals, and conferences based on reach, biased decision-making will play a greater role, often leading to delayed decision-making. This comes with risks: extended timelines correlate with increased project costs.

This is magnified when a first submission target becomes unfeasible due to gratuitous edit requests, rejection, or other factors, and the publications team must decide their subsequent target. Elsewhere, lack of reach data may also blind teams to valuable time-dependent opportunities such as early-bird submission mechanisms, or journals’ thematic special editions.

Meaningful reach metrics can therefore support critical project timelines, as well as greater understanding of publication audiences. Today’s audiences are more segmented than ever. Along with parameters such as geography or profession, the readership may represent an intended publication audience, a strategically targeted audience, or a novel audience.

Without comprehensive performance data such as reach metrics, it is more difficult to assess whether a critical audience has connected with a publication. The importance is in the name; without knowledge of reach, Medical Affairs and publications teams lack quantitative confirmation that audiences they seek are, in fact, seeing their research and development outputs.

Additionally, journal articles and conference abstracts may have unrecognized audiences of strategic interest to the Medical Affairs organization. Such groups are varied, and the medical strategy will define their role as (potential) stakeholders. Underappreciated audiences could include physicians in other therapeutic areas, nurses, pharmacists, allied healthcare professionals such as medical technicians, government and regulatory personnel, and patients and patient advocacy. It may be challenging to uncover these relevant groups without publication performance data such as reach. Missing these audiences limits publication influence. 

Metrics-grounded target selection supports Medical Affairs across the product lifecycle

In the life sciences industries, product lifecycle spans laboratory evaluation and clinical development, through regulatory approval and commercialization, followed by ongoing product support through post-marketing surveillance, real-world evidence generation, and curation of deeper business insights. As Medical Affairs’ strategic remit continues to expand across the lifecycle, publications teams are responsible for a growing scope of outputs.

With this increase in quantity comes increased complexity. As pharmaceutical drug products and medical technologies move through their product lifecycles, the scientific communications strategies supporting them must necessarily evolve. This occurs as the product profile matures, as further scientific and clinical data become available, as target audiences or geographies shift. Advanced preparation for these shifts allows the publication team to adapt efficiently. That advanced preparation derives in part from reliable publication performance data captured from trusted sources.

Whether maintaining existing publication targets or exploring new opportunities, the ability to track performance data over time promotes efficient decisions about data submission. The parameters that a given Medical Affairs team will prioritize will vary, but useful readouts include a journal’s length of peer review (from submission to publication), number of citations per published work per time period, and quantitative information about reach, engagement, and impact.

In this example, if length of review is steadily increasing, if newer publications are securing fewer citations than historical examples, and if quantitative altmetrics are decreased, it may be time to adjust the target. Clearly-defined, quantitative metrics promote efficient adaptation and serve the product lifecycle.

Such scientific communications performance data supports Medical Affairs in other strategic settings, too. Valuably, information about publication reach, engagement, and impact is available beyond the organization’s current products. This can reinforce market awareness and team readiness when moving into a new product modality or therapeutic area. As performance data are not limited to owned assets, key metrics may be tracked for competitor outputs. Understanding competitor publishing preferences for their long-form works and conference abstracts provides meaningful competitive intelligence insights to Medical Affairs and cross-functional colleagues.

When choosing publication targets, data-driven decision-making is capable decision-making

Now more than ever, performance metrics influence decisions about where, when, and how to publish in the life sciences industries. Scientific communications professionals see the importance of publication targeting based on benchmarks, and on performance data that is trackable over time. The ambiguities and delays of biased, emotionally-driven choices give way to traceability and efficiency.

Meanwhile, senior leadership are counting on metrics-grounded publication targeting that quantifies its value both for the readership and for the business. Using built-for-purpose measurement tools, the ability for Medical Affairs and publications teams to get this right underscores their strategic role as business partners within the organization.

Compass was designed to support data-driven decision-making for publications targeting. Built on Dimensions and Altmetrics data, Compass combines publication and altmetrics into a single collaborative workflow, simplifying how Medical Affairs teams benchmark, track, and manage publication impact and reach.

Compass by Dimensions is developed by Digital Science, an AI-focused technology company that transforms fragmented data into unified knowledge assets, leveraging AI and Knowledge Graphs to deliver structured, actionable intelligence for high-value discovery and innovation. By combining unparalleled data depth and breadth with enterprise-ready AI technology, we help leaders confidently accelerate product life cycles and secure a decisive market lead.

The post Moving from reputation to reach: data-driven decision-making for Medical Affairs publication targets appeared first on Digital Science.



from Digital Science https://ift.tt/PyHWsjM

From Vision to Velocity: Architecting a Functional AI Strategy for Medical Affairs

How are organizations architecting functional Artificial Intelligence (AI) strategies that will shape the next phase of AI in Medical Affairs?

Earlier this year, Digital Science brought together Medical Affairs leaders to explore how they’re approaching AI, and why they need to embed sustainable AI capabilities in day-to-day workflows. 

The conversation covered six key topics:

  1. Building trust and driving user adoption
  2. Managing the volume and quality of scientific insights
  3. Bridging the gap and demonstrating ROI 
  4. Governance, safety and regulatory alignment
  5. Systematic literature review and methodological rigour
  6. Emerging use cases

The journey from AI vision to operational velocity in Medical Affairs is one of deliberate, incremental progress rather than a single leap. The organizations making the most tangible progress are those pairing ambitious use cases with disciplined governance, keeping humans in the loop, insisting on provenance, and investing in the change management that turns adoption from an aspiration into a habit.

As AI capabilities mature and expand into new areas, from MSL training to patient journey research, the role of Medical Affairs will continue to evolve. Success will depend not on any single tool or model, but on the strategic architecture connecting people, processes, data and technology. By defining clear use cases, aligning stakeholders, protecting scientific integrity and demonstrating measurable value, Medical Affairs teams can indeed move from vision to velocity. And, therefore, lead their organizations in shaping how AI is applied responsibly in the service of science and patients.

The post From Vision to Velocity: Architecting a Functional AI Strategy for Medical Affairs appeared first on Digital Science.



from Digital Science https://ift.tt/OcXMiJW

How a lab came undone

The disinformation tax is the compounding cost of relying on findings that are false but not yet corrected, or corrected but not yet unlearned.

To understand this, we look at former Cornell researcher Brian Wansink, who published hundreds of studies on why we eat the way we do. But his research came under scrutiny, and the flags started — eventually touching 45 of his papers.

Here we track one piece of that tax: the citations his flagged papers kept collecting after a problem was already on the record.

Each vertical line is one of his flagged papers, in the order they were published. Grey and blue ticks are citations — blue when the citation comes from Wansink himself.

↓ Scroll to begin
accumulated
0
total citations
the tax
0
citations after a flag
from within
0
self-citations after a flag
PubPeer
0
Corrections
0
Exp. concern
0
Retractions
0
Where it lands

The record kept spreading, even after the flags

0
total citations to the 45 flagged papers
0
of them made after the paper was flagged
0
self-citations after the flag — the lab stopped citing itself

Lines are ordered by publication date; a line's colour changes to the flag it received — green PubPeer, orange correction, purple expression of concern, red retraction — and a $ marks papers linked to a funding grant. The vertical scale is stretched across 2012–2022, where most flags fall. Citation ticks and all counters are year-resolution. Sources: Dimensions.ai and the Retraction Watch database. This page reports the public record and alleges no wrongdoing beyond the recorded editorial actions.

See the detailed interactive ledger →

The post How a lab came undone appeared first on Digital Science.



from Digital Science https://ift.tt/EmyiQDk

Featured Post

52nd Edition of GSC Awards-25–26 January 2027-Tokyo, Japan - Shinagawa Prince Hotel

  The Global Scholar Awards is an international recognition platform dedicated to celebrating outstanding researchers, academicians, scienti...

Popular